Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06682572 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Study acronym: RAMP201J
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 15 to confirmed 16 · Site details revised at 5 of 5 sitesv5 Show 2 more changesShow less
    • Enrollment target: estimated 15 to confirmed 16
    • Site details revised at 5 of 5 sites
  2. Site details revised at 5 of 5 sitesv4
  3. Site details revised at 1 of 5 sitesv3
  4. Interventions: Avutometinib (VS-6766) + defactinib (Drug) to Avutometinib (VS-6766) + Defactinib (VS-6063) (Drug)v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will confirm the safety and efficacy of avutometinib in combination with defactinib in Japanese patients with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Trial Details
NCT Number NCT06682572
Lead Sponsor Verastem, Inc.
Collaborators: Japanese Gynecologic Oncology Group
Conditions Low Grade Serous Ovarian Cancer, Ovarian Cancer
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov